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Methods:
 
We conducted a multinational pharmacoeco-
 
nomic evaluation comparing the immediate release form
of a new class of serotonin norepinephrine reuptake in-
hibitor (SNRI), venlafaxine IR to the selective serotonin
reuptake inhibitors (SSRIs) and the tricyclic antidepres-
sants (TCAs) in the treatment of acute major depressive
disorder (MDD) in 10 countries (Germany, Italy, Neth-
 
erlands, Poland, Spain, Sweden, Switzerland, United King-
dom, United States, and Venezuela). We designed a deci-
sion analytic model assessing the acute phase of MDD
treatment within a 6-month time horizon. Six decision tree
models were customized with country-specific estimates
from a clinical management analysis, meta-analytic rates
from two published meta-analyses, and a resource valu-
ation of treatment costs representing the inpatient and
outpatient settings within each country. The meta-anal-
yses provided the clinical rates of success defined as a
50% reduction in depression scores on the Hamilton
Depression Scale (HAM-D) or the Montgomery-Asberg
Depression Rating Scale (MADRS). Treatment regimen
costs were determined from standard lists, fee schedules,
 
and communication with local health economists in each
country. The meta-analytic rates were applied to the de-
cision analytic model to calculate the expected cost and
expected outcomes for each antidepressant comparator.
Cost-effectiveness was determined using the expected
values for both a successful outcome, and a composite
measure of outcome termed symptom-free days. A pol-
icy analysis was conducted to examine the health system
budget impact in each country of increasing the utiliza-
tion of the most effective antidepressant found in our
study.
 
Results:
 
Initiating treatment of MDD with venlafaxine
IR yielded a lower expected cost compared to the SSRIs
and TCAs in all countries except Poland in the inpatient
setting, and Italy and Poland within the outpatient set-
tings. The weighted average expected cost per patient
varied from US$632 (Poland) to US$5647 (US) in the six-
month acute phase treatment of MDD. The estimated to-
tal budgetary impact for each 1% of venlafaxine utiliza-
tion, assuming a population of one million MDD patients,
ranged from US$1600 (Italy) to US$29,049 (US).
 
Conclusions:
 
Within the inpatient and outpatient treat-
ment settings, venlafaxine IR was a more cost-effective
treatment of MDD compared to the SSRIs and TCAs.
Additionally, the results of this investigation indicate
that increased utilization of venlafaxine in most settings
across Europe and the Americas will have favorable im-
pact on health care payer budgets.
ADR, adverse drug reaction; CMA, clinical manage-
ment analysis; ECT, electroconvulsive therapy; HAM-D,
 
Hamilton Depression Scale; MADRS, Montgomery-
Asberg depression rating scale; MDD, major depressive
disorder; SFD, symptom-free day; SNRI, serotonin-nor-
epinephrine reuptake inhibitor; SSRI, selective seroto-
nin reuptake inhibitor; TCA, tricyclic antidepressant;
WHO, world health organization.
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Introduction
 
Major depressive disorder (MDD) represents a sig-
nificant public health problem in the new millen-
nium 2000, posing a substantial burden of illness
 
to health care providers, payers, and patients world-
wide. Additionally, it is projected that by the year
2020, depression will rank second in disease bur-
den measured in Disability-Adjusted Life Years
(DALYS) [1].
 
Intuitively, the economics of diagnosing and treat-
ing this disease is daunting. It was estimated in 1993
 
Address correspondence to: 
 
 John Doyle, The Analytica
Group, 475 Park Avenue South, 17th Floor, New York,
NY 10016. E-mail: jdoyle@groupanalytica.com
 Multinational Pharmacoeconomic Evaluation of MDD
 
17
 
that the three leading types of depression (manic
depression, major depression and dysthymia) cost
the United States US$43.7 billion a year [2], which
is approximately equal to the cost of treating heart
disease [3]. European countries have also reported
significant cost of illness. In the United Kingdom,
for example, Kind estimated that in 1993 depres-
sion cost some £420 million annually [4].
As imposing as these estimates of the economic
burden of depression seem, it is quite possible that
these findings underestimate the true cost of de-
pression, because they represent only the cost of
treating diagnosed depression. According to the
WHO [5], depression is estimated to be present in
10% of all patients seeking care at primary health
care facilities worldwide, but it is frequently unrec-
ognized by primary care physicians. The DEPRES
study attempted to quantify this and showed that
only 41% of those suffering from major depres-
sion received medication [6]. In terms of indirect
costs, the DEPRES study also showed that MDD
has a deleterious impact on productivity measured
in days-of-work-lost; on average MDD patients lost
13 days over six months vs. three days for nonsuf-
ferers [6]. Astonishingly, the rate of suicides for
those suffering from major depression has been es-
timated to be between 10% and 15%, accounting
for 60% to 70% of all suicides [7].
The ratio of health care expenditure to gross do-
mestic product continues to rise among the indus-
trialized nations, driven in part by the aging popu-
lation, and also by the increasing cost of health care
services and medical technology advancements. Of
the 10 countries examined in this research, only It-
aly and Spain have experienced decreases in this ra-
tio from 1990 to 1996 as reported by the Organiza-
tion for Economic Cooperation and Development
(OECD) [8] and local health economists. Health
care policy decision-makers around the world are
increasingly instituting measures to control the es-
calating costs of health care, from the development
of guidelines and disease-management initiatives to
the capitation of health care expenditures.
Cost-containment initiatives worldwide specific
to MDD have traditionally focused on market prices
of pharmaceutical interventions to curb treatment
costs, particularly with respect to the newer antide-
pressants such as selective-serotonin reuptake inhibi-
tors (SSRIs). For example in 1993, government
funding in Italy was reduced or eliminated for sev-
eral hundred products, including SSRIs. Although
controlling drug expenditures represents a rela-
tively simple and perhaps effective target for short-
term policy-making, the cost-effective treatment of
MDD for long-term health care policy will depend
on evaluation of all resources consumed during the
treatment process. The newer antidepressants, gen-
erally with higher acquisition costs than the older
drugs such as tricyclics (TCAs), generate tangible
benefits, such as an improved efficacy and safety
profiles. These clinical benefits must be economi-
cally quantified and compared to facilitate the ef-
fective and efficient allocation of mental health care
resources. Toward that end, comprehensive phar-
macoeconomic evaluation is warranted to assess to-
tal direct costs and cost-effectiveness of competing
antidepressants.
In recent years, a number of pharmacoeco-
nomic studies of MDD treatment have been con-
ducted and have produced varied conclusions re-
garding the patient-level implications of alternative
treatment options [9–21]. This research represents
the first attempt to investigate patient-level implica-
tions of antidepressant treatment in 10 countries,
and to quantify those findings in terms of popula-
tion level impact on health care budgets of primary
payers in each market.
 
Methods
 
We performed a cost-effectiveness comparison be-
tween venlafaxine (IR) the immediate release form
of the serotonin-norepinephrine reuptake inhibitor
(SNRI) class vs. two other classes of antidepres-
sants, the selective serotonin reuptake inhibitors
(SSRIs) and the tricyclic antidepressants (TCAs) in
the following 10 countries: Germany, Italy, Nether-
lands, Poland, Spain, Sweden, Switzerland, United
Kingdom, United States, and Venezuela. The struc-
tural design of our decision-tree model illustrated in
Figure 1 and the clinical outcomes data of each com-
parator shown in Table 1 were based on a previous
pharmacoeconomic analysis performed in Canada
[21] and two recently published meta-analyses [22,
23]. A policy-level analysis estimated the budgetary
impact that greater venlafaxine utilization would
have on the public or private payers responsible for
treatment of acute MDD within the respective pop-
ulations of the 10 countries.
 
Research Perspective
 
We analyzed the health care reimbursement sys-
tems of all 10 countries to identify and address the
dominant payer perspective [24–39]. With the ex-
ception of the United States, the majority of health
care funding is public (Table 2). Therefore, for all
countries studied but the US, our research was con-
ducted from the perspective of the government body
 18
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responsible for health care reimbursement. In the
United States, a managed care perspective was
used in the evaluation.
 
Analytic Time Horizon
 
After examining the available clinical outcomes data
for acute MDD and the opinion of mental health care
providers within each of the countries, we deter-
mined that a 6-month time horizon was an appropri-
ate assessment period for treatment in the acute
phase of MDD. Specifically, since there is little avail-
able clinical trial data assessing relapse rates in pa-
tients with acute MDD, our timeline was restricted
to 6-months to limit the potential information bias.
 
Data Sources
 
Meta-analytic Rates
 
Table 1 depicts the clinical
outcomes data, representing success rates and drop-
out rates that were derived from two meta-analyses
conducted by Einarson and colleagues in 1998 [20]
reporting the rates of the immediate release form
of venlafaxine IR and a more recent meta-analysis
(1999) reporting the rates for the SSRIs and TCAs
[21]. The success rates for each of the three compar-
ators were defined in the meta-analysis as a 50% re-
duction in depression scores on the Hamilton Rating
Scale for Depression (HAM-D) or the Montgomery-
 
Ashberg Depression Rating Scale (MADRS). Drop-
out rates were defined by the probabilities of failing
treatment due to patient perceived lack of improve-
ment (efficacy) or due to adverse drug reactions
(ADRs) [20, 21].
 
Decision Tree Model
 
Figure 1 illustrates the pre-
dictive decision tree model designed by Einarson
and colleagues (1997) to represent the possible out-
comes of a hypothetical patient treated for acute
MDD in the inpatient and/or outpatient setting over
a six-month time period. The decision tree probabil-
ities of each branch were determined through the
meta-analysis and clinical management analysis. Ef-
ficacy and dropout rates obtained from the meta-
analysis were assumed to be the same across coun-
tries, however, country-specific assumptions were
derived from the opinion of local experts to ac-
count for differences in the choice of medical treat-
ment options.
 
Clinical Management Analysis
 
A clinical management analysis (CMA) was per-
formed to estimate the country-specific treatment
options and outcomes within the set structure of
the decision tree model [19] seen in Figure 1. A to-
tal of 42 mental health clinicians were consulted
to perform this analysis. Surveys were sent to the
participating physicians and follow-up interviews
 
Table 1
 
Meta-analytic rates
 
Success rates
Inpatient Outpatient
Treatment No. of patients Rates 95% CI No. of patients Rates 95% CI
Venlafaxine IR* 164 0.623 0.497–0.749 299 0.702 0.617–0.788
 
SSRIs
 
†
 
84 0.586 0.482–0.690 2,496 0.614 0.557–0.670
TCAs
 
†
 
325 0.582 0.430–0.735 727 0.593 0.501–0.686
Dropout rates
Lack of efficacy Adverse drug reactions (ADRs)
Treatment No. of patients Rates 95% CI No. of patients Rates 95% CI
Venlafaxine IR* 734 0.056 0.018–0.076 801 0.159 0.113–0.204
SSRIs
 
†
 
823 0.084 0.046–0.123 823 0.084 0.046–0.123
TCAs
 
†
 
865 0.068 0.046–0.090 866 0.231 0.162–0.300
 
*Rates for venlafaxine IR are taken from Einarson et al. (1998).
 
†
 
Rates for the SSRIs and TCAs are adapted from Einarson et al. (1999). SSRIs, selective serotonin reuptake inhibitors; TCAs, tricyclic antidepressants.
 
Table 2
 
Public expenditures as a percent of total health 
expenditures
 
Country Primary payer Percent of total health expenditures
Germany Public 78%
Italy Public 70%
Netherlands Public 77%
Poland Public 81%*
Spain Public 76%
Sweden Public 80%
Switzerland Public 73%
UK Public 84%
USA HMO 47%
Venezuela Public 80%*
 
OECD Health data, 1997.
*Information provided by local health economist.
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were conducted to establish consensus within each
of the 10 countries. Six decision trees, representing
the three treatment comparators within the inpa-
tient and outpatient setting, were customized within
each country to identify the number of physician
and psychiatric visits; diagnostic tests, hospitaliza-
tion days, comparator treatment dosing schedules
and additional therapies required at each decision
node within each branch in the decision tree. Inpa-
tient and outpatient trees only differed by health
care resources identified for each treatment com-
parator and decision probabilities of branches 1–26
(Fig. 1). Furthermore, the CMA also determined the
probabilities of titration, augmentation, combination
and switching to second-line therapies within the spe-
cific decision node probabilities for each treatment
comparator.
 
Treatment Comparators
 
Similar to the Canadian model developed by Ein-
arson et al. [19] results are presented at the drug
class level. In all 10 countries, the reference drug,
venlafaxine (a serotonin norepinephrine reuptake
inhibitor, SNRI) was compared to two classes of an-
tidepressants: the selective serotonin reuptake inhibi-
tors (SSRIs) and the tricyclic antidepressants (TCAs).
The CMA Participants in each country also deter-
mined the most commonly prescribed antidepres-
sants within the SSRI and TCA classes. The SSRI
class was represented by at least two of the following
(fluoxetine, fluvoxamine, paroxetine, sertraline and
citalopram) while the TCA class was represented
by at least three of following (fluoxetine, fluvox-
amine, paroxetine, sertraline and citalopram) in
each country. The average values of the individual
drugs, which constitute each class, were used to
calculate aggregated results.
 
Health Care Resource Valuation
 
A total of 14 health economists within each coun-
try identified the unit costs from standard lists for
the antidepressant comparators and medical re-
sources identified by the clinical management anal-
ysis. An average weighted cost was calculated for
the relevant SSRIs and TCAs to establish a repre-
sentative cost per class in each country. Further-
more, each inpatient and outpatient decision tree
differed by resource valuations. For example, in
 
Table 3
 
Resource valuation of acute MDD treatment
 
Germany Italy Netherlands Poland Spain Sweden Switzerland UK USA Venezuela
National Currency 
Unit (NCU) DM Lira NLG PLN Ptas. SEK Sfr £ $ Bs
Exchange rate
(NCU/US$) 0.57 0.00059 0.51 0.28 0.0068 0.13 0.68 1.62 1.00 0.002
Physician services
Physician (GP)
inpatient $44 $24 $72 $8 $77 $62 $85 $148 $177 $60
Physician (GP) 
outpatient $45 $24 $19 $6 $6 $98 $75 $24 $158 $40
Physician
(Psychiatrist):
inpatient $128 $22 $105 $5 $77 $85 $94 $148 $140 $60
Physician
(Psychiatrist):
outpatient $124 $22 $105 $5 $73 $85 $101 $148 $140 $50
Laboratory services
Electrocardiogram 
(ECG) $20 $13 $19 $6 $20 $34 $94 $165 $54 $10
Computed
Tomagraphy
(CT) scan $6 $95 n/a $41 $138 $257 $408 $126 $3,545 $90
Facility services
Hospital $446 $241 $299 $54 $285 $308 $255 $227 $800 $660
Electroconvulsive 
therapy (ECT)
Facility (Hospital) 
component $106 $128 $61 $40 $120 $208 $680 $113 $200 n/a
Pharmacotherapy Average daily cost
Venalafaxine $4.45 $3.57 $1.46 $1.99 $1.28 $1.81 $1.95 $1.70 $2.46 $2.76
Average for SSRI’s $3.18 $1.07 $1.16 $0.92 $0.81 $1.32 $2.07 $2.22 $2.52 $2.44
Average for TCA’s $2.34 $1.07 $0.51 $0.11 $0.23 $0.35 $0.99 $0.26 $0.25 $1.07
 
GP, general practitioner; SSRIs, selective serotonin reuptake inhibitor; TCAs, tricyclic antidepressants.
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the United Kingdom, a general practitioner gener-
ally manages a patient with acute MDD in the out-
patient setting, while a psychiatrist strictly manages
these patients in the inpatient setting. Hence, treat-
ment with any of the three comparators will incur a
lower cost in the outpatient vs. inpatient settings
in all countries. Table 3 compares a selection of
the most significant health care resources, which
were, along with other relevant resources and costs,
incorporated into distinct decision trees to estimate
the total expected costs per comparator within the
inpatient and outpatient settings in each country.
All costs in Table 2 were represented in 1999 US
dollars. Considerable variance in resources and their
associated costs between countries precluded a more
extensive representation of the resource valuation
table.
 
Pharmacoeconomic Analysis
 
The pharmacoeconomic analysis employed three an-
alytic types: Consequence Analysis, Expected Cost/
Outcome Analysis, and Cost-Effectiveness Analysis.
Consequence Analysis identifies all of the health out-
comes associated with each of the treatment path-
ways in the decision analytic model. The primary
outcome identified for this evaluation was treatment
success, calculated by multiplying the success rates,
drop-out rates due to lack of efficacy or adverse drug
reactions in Table 1.
Expected success rates were calculated by sum-
ming the probabilities in each branch (determined
in the CMA) of the decision tree for a successful
outcome prior to the end of the 6-month time ho-
rizon. The secondary outcome measure of this eval-
uation was symptom-free days (SFDs). SFDs were
defined as six months minus the time elapsed before
clinical determination of success. Due to the lack of
availability of published quality-of-life data, this pa-
rameter estimate was a proxy for patient utility. For
each branch of the decision tree terminating in a suc-
cessful treatment, the time after the determination of
successful treatment until the end of the 6-month
time period was considered symptom-free. It was as-
sumed that there would be zero SFDs for any path-
way terminating prior to treatment success.
Unlike cost-consequence analysis, Expected Cost/
Outcome Analysis incorporates the probabilities
from the decision analytic model. Chance nodes in
the model were evaluated based on success and fail-
ure rates, which were determined through meta-
analysis for each of the treatment comparators. De-
cision nodes were evaluated through consultation
with clinical experts. For example, as shown in Fig. 1,
the chance of success after primary treatment with an
 
SSRI, was derived through efficacy rates determined
in the meta-analysis [20]. In contrast, the decision to
treat with electroconvulsive therapy (ECT) after fail-
ure on secondary drug treatment was determined
though country-specific physician consensus.
Cost-Effectiveness Analysis was conducted by
combining the expected cost with primary and
secondary outcome measures. The following cost-
effectiveness endpoints were calculated: 1) expected
cost per success; and 2) expected cost per SFD. In-
cremental cost-effectiveness ratios (ICERs) were
also calculated to determine the incremental cost
per success and the incremental cost per SFD in
treatment settings whereby venlafaxine IR did not
result in the lowest expected cost of treatment al-
ternative.
 
Sensitivity Analysis
 
Two sensitivity analyses were performed to test
assumptions implicit to the model. Univariate or
break-even analyses were conducted by varying
the success rates and unit costs of venlafaxine in-
dependently to determine the break-even point at
which venlafaxine’s expected cost would equal the
expected cost of the SSRIs and the TCAs within
each country.
In addition, a series of multivariate analyses
were conducted using a Monte Carlo simulation,
which generated 10,000 iterations by varying the
inputs for unit costs of venlafaxine IR and the other
class comparators as well as the success and drop-
out rates for both primary and secondary therapy
for each of the comparators. Success and failure
rates were varied randomly within the 95% confi-
dence interval based on a truncated normal distri-
bution. Costs of resources used for services pro-
vided throughout therapy were varied randomly
within 
 

 
 20% of the estimated cost based on a
uniform distribution. The Monte Carlo simulation
calculated the mean and standard deviation values
for the difference in expected cost and expected
SFDs between venlafaxine and either the SSRI or
TCA class comparators.
 
Policy Analysis
 
To facilitate population-level decision-making among
the target audiences for this study, we conducted a
policy analysis that extrapolated the patient-level re-
sults to provide an estimated budgetary impact of in-
creased utilization of venlafaxine IR. The approach
followed for the budget impact analysis is outlined
in Figure 2.
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Results
 
Decision-Tree Probabilities
 
Decision probabilities were calculated for each of
the 26 possible outcomes or branches for 60 deci-
sion trees representing all 10 countries, each as-
sessing treatment patterns and outcomes of the
three treatment comparators in two treatment set-
tings. As an example, Table 4 depicts the decision
probabilities calculated for the inpatient and out-
patient settings for each of the comparators in Ger-
many. As shown in branch 1 of Table 4, the high-
est rate of success resulted from the first-line
treatment with venlafaxine IR at 51% and 57%
followed by first-line treatment with the SSRIs at
45% and 46%, and lastly, 41% and 38% with the
TCAs in the inpatient and outpatient settings, re-
spectively. Mental health experts in Germany de-
termined that antidepressant combination therapy
was not a therapeutic option for outpatients. Out-
patient treatment of MDD in the acute phase poses
a higher risk of adverse drug interactions due to
less medical monitoring compared to the inpatient
setting. As such, the decision probabilities for com-
bination therapy were zero for the outpatient deci-
sion tree in Germany (branches 11–14). Moreover,
the clinical management analysis in Germany also
identified the second-line treatment typically pre-
scribed following first-line failure for each com-
parator. In the event of failure of first-line treat-
ment with venlafaxine or the SSRIs, the TCAs were
the second-line or back-up alternative. In contrast,
the SSRIs were the second-line or back-up treat-
ment following failure of first-line treatment with
the TCAs. This is one reason why the probabilities
of success for the second-line treatments (branch
19) were consistently higher with the TCAs using
SSRIs as back up vs. venlafaxine IR and the SSRIs,
which used TCAs as back-up. The other obvious
reason is that the higher initial success rates of
venlafaxine IR invariably drove down the proba-
bilities of failure due to titration, augmentation,
and adverse drug reactions vs. the comparators.
 
Pharmacoeconomic Analysis
 
Table 5 provides the results of the inpatient and
outpatient expected costs associated with each treat-
ment in all 10 countries. Within the inpatient set-
ting, acute MDD treatment with venlafaxine re-
sulted in a lower expected cost vs. treatment with
SSRIs or TCAs in all countries with the exception
of Poland where treatment with venlafaxine was
estimated at $1433 vs. $1314 for the SSRIs and
TCAs during the six month period. Within the
outpatient settings, treatment with venlafaxine was
 
Table 4
 
Decision probabilities: example for Germany
 
Inpatient Outpatient
Branch Treatment outcome Venlafaxine SSRIs TCAs Venlafaxine SSRIs TCAs
1 First-line success 0.5110 0.4455 0.4096 0.5780 0.4615 0.3836
2 Success following titration 0.0177 0.0171 0.0142 0.0162 0.017 0.0143
3 Failure titration, Success augmentation 0.0042 0.0053 0.0051 0.0030 0.005 0.0057
4 Failure titration, failure augmentation, hospitalization 0.0014 0.0017 0.0016 0.0015 0.0024 0.0028
5 Failure titration, failure augmentation, extra psycho-tx 0.0028 0.0035 0.0033 0.0015 0.0024 0.0028
6 Failure titration, failure augmentation, ECT 0.0002 0.0002 0.0002 0.0001 0.0001 0.0002
7 Failure titration, success 2nd-line 0.0035 0.0044 0.0046 0.0023 0.0038 0.0053
8 Failure titration, failure 2nd-line, hospitalization 0.0016 0.002 0.0018 0.0018 0.003 0.003
9 Failure titration, failure 2nd-line, extra-psycho-tx 0.0033 0.0041 0.0037 0.0018 0.003 0.003
10 Failure titration, failure 2nd-line, ECT 0.0002 0.002 0.0002 0.0001 0.0002 0.0002
11 Success combination 0.0123 0.0136 0.0123 0 0 0
12 Failure combination, hospitalization 0.0016 0.0018 0.0016 0 0 0
13 Failure combination, extra psycho-tx 0.0033 0.0036 0.0033 0 0 0
14 Failure combination, ECT 0.0002 0.0002 0.0002 0 0 0
15 Success augmentation 0.0087 0.0096 0.0086 0.0211 0.0276 0.0279
16 Failure augmentation, hospitalization 0.0028 0.0031 0.0028 0.0103 0.0134 0.0136
17 Failure augmentation, extra-psycho-tx 0.0056 0.0003 0.005 0.0103 0.0134 0.0136
18 Failure augmentation, ECT 0.0003 0.0003 0.0003 0.0006 0.0008 0.0008
19 Success 2nd-line tx 0.1137 0.126 0.1235 0.0812 0.106 0.1289
20 Failure 2nd-line tx, hospitalization 0.0524 0.0581 0.0492 0.0633 0.0826 0.0729
21 Failure 2nd-line tx, extra-psycho-tx 0.0524 0.118 0.0999 0.0633 0.0826 0.0729
22 Failure 2nd-line tx, ECT 0.1065 0.0054 0.0046 0.0039 0.0051 0.0045
23 ADR failure, 2nd-line success 0.0049 0.0696 0.1087 0.0545 0.0652 0.1126
24 ADR failure, 2nd-line failure, hospitalization 0.0269 0.0321 0.0433 0.0425 0.0508 0.0637
25 ADR failure 2nd-line failure, extra-psycho-tx 0.0546 0.0652 0.0879 0.0425 0.0508 0.0637
26 ADR failure 2nd-line failure, ECT 0.0026 0.003 0.0041 0.0026 0.0031 0.0039
 
SSRIs, selective serotonin reuptake inhibitors; TCAs tricyclic antidepressants; ECT, electroconculsive therapy.
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associated with a lower cost in all countries, other
than Poland and Italy where the acquisition costs
of the TCAs and even SSRIs were significantly
lower than venlafaxine as seen in Table 4.
Table 6 compares the success rates calculated in
the country specific decision trees for each treat-
ment comparator based on the efficacy rates fol-
lowing initial treatment in the inpatient or outpa-
tient setting. Initiating treatment of acute MDD
with venlafaxine yielded superior outcomes in
terms of expected success rates for inpatients and
outpatients vs. TCAs and SSRIs in all countries
examined (Table 5). Based on the costs and suc-
cess rates calculated within the decision tree model
for each treatment, we determined the expected
cost per success as depicted in Table 7. Venlafax-
ine was more cost-effective than the SSRI and TCA
classes in 8 of the 10 countries within the outpatient
setting and in 9 of the 10 countries within the inpa-
tient setting. Among the 9 countries in which ven-
lafaxine ranked first in expected cost per success,
the difference in expected cost per success for ven-
lafaxine and the second ranking comparator ranged
from US$66 (Italy) to US$1617 (US) for outpa-
tients, and from US$524 (UK) to US$3750 (US) for
inpatients.
Furthermore, the treatment specific decision trees
representing the inpatient and outpatient settings
also estimated the number of Symptom-Free Days
(SFDs) as shown in Table 8. Since venlafaxine was a
more effective treatment, it therefore resulted in a
higher number of SFDs vs. SSRIs and TCAs in all
countries regardless of inpatient or outpatient setting.
Table 9 shows the results of the estimated cost per
symptom-free day for each patient treated with ei-
ther comparator as an inpatient or outpatient. In the
countries where venlafaxine ranked first in expected
cost per SFD, the difference in expected cost per SFD
for venlafaxine and the second ranking comparator
(SSRIs) ranged from US$1 (Italy) to US$14 (US) for
outpatients, and from US$6 (UK) to US$33 (US) for
inpatients.
 
Incremental Cost-effectiveness Ratios (ICERs)
 
Table 10 presents the incremental cost-effective-
ness ratios (ICERs) calculated in Italy and Poland
 
Table 5
 
Expected cost
 
Expected cost-inpatient summary
Drug treatment Germany Italy Netherlands Poland Spain Sweden Switzerland UK USA Venezuela
venlafaxine $11,909 $9,036 $12,853 $1,433 $7,686 $8,299 $11,883 $7,956 $16,235 $25,391
SSRIs $12,747 $9,399 $14,143 $1,314 $7,955 $8,664 $12,411 $8,318 $17,843 $26,489
TCAs $12,907 $9,567 $14,307 $1,314 $8,053 $8,801 $12,610 $8,540 $18,135 $27,449
Expected cost-outpatient summary
Drug treatment Germany Italy Netherlands Poland Spain Sweden Switzerland UK USA Venezuela
venlafaxine $2,556 $973 $1,274 $495 $1,408 $2,233 $2,454 $1,845 $3,427 $2,374
SSRIs $3,046 $979 $1,510 $339 $1,552 $2,449 $2,645 $2,065 $4,300 $2,469
TCAs $3,077 $935 $1,544 $331 $1,539 $2,424 $2,647 $2,132 $4,317 $2,828
 
SSRI’s, selective serotonin reuptake inhibitors; TCAs, tricyclic antidepressants.
 
Table 6
 
Expected success rates
 
Expected success rates-inpatient summary
Drug treatment Germany Italy Netherlands Poland Spain Sweden Switzerland UK USA Venezuela
venlafaxine 73.3% 78.0% 74.0% 74.6% 76.7% 75.8% 77.2% 74.5% 75.6% 74.9%
SSRIs 69.3% 74.2% 68.9% 70.7% 72.8% 71.8% 75.7% 74.2% 70.7% 73.8%
TCAs 69.0% 72.9% 68.6% 70.1% 71.7% 70.9% 74.2% 70.0% 70.1% 69.5%
Expected success rates-outpatient summary
Drug treatment Germany Italy Netherlands Poland Spain Sweden Switzerland UK USA Venezuela
venlafaxine 76.9% 80.3% 78.3% 77.2% 80.0% 79.3% 81.5% 78.0% 80.2% 78.8%
SSRIs 70.7% 74.4% 70.5% 70.9% 74.1% 73.2% 79.4% 77.6% 73.0% 77.3%
TCAs 70.2% 73.2% 70.1% 70.5% 73.0% 72.2% 77.5% 71.2% 72.2% 70.8%
 
SSRIs, selective serotonin reuptake inhibitors; TCAs, tricyclic antidepressants.
 Multinational Pharmacoeconomic Evaluation of MDD
 
25
 
since these were the only treatment settings in
which venlafaxine IR was not the lowest treatment
cost alternative. Within the outpatient setting in It-
aly, the TCAs resulted in a lower expected cost de-
spite a higher success rate vs. venlafaxine IR by a
difference in cost and success rate of $38 (US) and
5.1%, respectively, As a result, venlafaxine showed
a highly favorable ICER measured in terms of the
incremental cost per success and the incremental
cost per SFD, $1278 and $410, respectively (Table
10). In Poland, greater differences in expected
costs between venlafaxine and its comparators re-
sulted in less favorable ICERs, with incremental cost
per success and cost per SFD of $2448 and $14, re-
spectively, relative to the TCAs in the outpatient set-
ting. In the inpatient setting, these went as high as
$3061 and $20, respectively, relative to the SSRIs
(Table 10).
 
Policy Analysis
 
Our analysis revealed that in all settings venlafax-
ine maintained the highest expected success rate
 
Table 7
 
Expected cost per success
 
Expected cost per success-inpatient summary
Drug treatment Germany Italy Netherlands Poland Spain Sweden Switzerland UK USA Venezuela
venlafaxine $16,257 $11,590 $17,367 $1,921 $10,027 $10,951 $15,398 $10,683 $21,474 $33,920
SSRIs $18,381 $12,668 $20,513 $1,858 $10,934 $12,068 $16,386 $11,207 $25,224 $35,872
TCAs $18,707 $13,126 $20,848 $1,876 $11,224 $12,411 $16,999 $12,208 $25,882 $39,503
Expected cost per success-outpatient summary
Drug treatment Germany Italy Netherlands Poland Spain Sweden Switzerland UK USA Venezuela
venlafaxine $3,322 $1,212 $1,628 $641 $1,759 $2,814 $3,012 $2,365 $4,276 $3,012
SSRIs $4,311 $1,315 $2,141 $478 $2,093 $3,344 $3,331 $2,662 $5,893 $3,192
TCAs $4,382 $1,278 $2,201 $470 $2,108 $3,355 $3,417 $2,994 $5,981 $3,993
 
SSRIs, selective serotonin reuptqake inhibitors; TCA’s, tricyclic antidepressants.
 
Table 8
 
Expected symptom-free days
 
Expected symptom-free days-inpatient summary
Drug treatment Germany Italy Netherlands Poland Spain Sweden Switzerland UK USA Venezuela
venlafaxine 96 100 89 93 107 98 96 97 94 105
SSRIs 89 93 82 87 100 91 93 94 87 102
TCAs 88 91 80 86 98 89 90 89 86 96
Expected symptom-free days-outpatient summary
Drug treatment Germany Italy Netherlands Poland Spain Sweden Switzerland UK USA Venezuela
venlafaxine 102 105 96 98 113 104 102 103 101 112
SSRIs 91 94 84 88 102 93 97 98 90 106
TCAs 89 91 82 86 99 91 93 90 88 97
 
SSRIs, selective serotonin reuptake inhibitions; TCAs, tricyclic antidepressants.
 
Table 9
 
Expected cost per symptom-free day
 
Expected cost per symptom-free day-inpatient summary
Drug treatment Germany Italy Netherlands Poland Spain Sweden Switzerland UK USA Venezuela
venlafaxine $124 $90 $144 $15 $72 $85 $124 $82 $172 $242
SSRIs $143 $101 $173 $15 $80 $95 $134 $88 $205 $261
TCAs $147 $105 $179 $16 $83 $99 $140 $96 $212 $287
Expected cost per symptom-free day-outpatient summary
Drug treatment Germany Italy Netherlands Poland Spain Sweden Switzerland UK USA Venezuela
venlafaxine $25 $9 $13 $5 $12 $21 $24 $18 $34 $21
SSRIs $33 $10 $18 $4 $15 $26 $27 $21 $48 $23
TCAs $34 $10 $19 $4 $15 $27 $28 $24 $49 $29
 
SSRIs, selective serotonin reuptake inhibitors; TCAs, tricyclic antidepressants.
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and greatest number of SFDs. Additionally, ven-
lafaxine yielded the lowest expected cost of treat-
ing MDD patients in 8 of the 10 health care settings
for outpatients and 9 of the 10 for inpatients. There-
fore, we evaluated the local budgetary impact of a
shift in reimbursement from the payers’ current port-
folio of antidepressant spending, to one with a greater
percentage of spending allocated to venlafaxine.
The weighted average expected cost per patient
(W
 
EC
 
, in Analytic Approach, section 2.1) for treat-
ing MDD ranged from US$632 (Poland) to US$5647
(US). Table 11 illustrates these results, as well as the
total estimated direct cost for MDD treatment and
the estimated cost to the primary payer in each coun-
try (CDC and CDC
 
P
 
, respectively, in Analytic Ap-
proach, section 2.2). To facilitate interpretation of
the results, the savings (or loss) is based on the
population assumption of one million covered lives
(i.e., patients eligible for reimbursement for men-
tal health care services) and a conservative treated
prevalence of 0.3% for each country.
 
Sensitivity Analysis
 
The results of the univariate and multivariate sen-
sitivity analyses indicate that our patient-level find-
ings are robust with respect to assumptions im-
plicit to the model. For all countries, the results of
the break-even analyses illustrated in Tables 12 and
13 showed that venlafaxine IR is equally cost-effec-
tive vs. SSRIs and TCAs, even with modest to sub-
stantial variations in venlafaxine’s success rate and
drug price. For example, in Table 12 the break-even
analysis for daily cost of treatment within the inpa-
tient setting in Germany suggests that venlafaxine,
 
Table 10
 
Incremental cost-effectiveness ratios (ICERs) for venlafaxine in Italy and Poland
 
Italy Poland
Treatment setting Outpatient Inpatient Outpatient
Comparator TCAs SSRIs TCAs SSRIs TCAs
Venlafaxine ICERs:
Incremental cost/success $1,278 $3,061 $2,634 $2,476 $2,448
Incremental cost/SFD $10 $20 $17 $16 $14
 
TCAs, tricyclic antidepressants, SSRIs, selective serotonin reuptake inhibitors; SFD, symptom-free day.
 
Table 11
 
Results of the policy-level analysis*
 
Germany Italy Netherlands Poland Spain Sweden Switzerland UK USA Venezuela
Payer perspective Public Public Public Public Public Public Public Public HMO Public
Inpatient—weighted 
average cost per
patient $12,795 $9,474 $14,177 $1,317 $7,991 $8,713 $12,490 $8,415 $17,936 $26,921
Outpatient—weighted 
average cost per
patient $3,043 $957 $1,518 $338 $1,540 $2,428 $2,640 $2,091 $4,282 $2,640
MDD treatment
—weighted average
expected cost per 
patient $5,481 $2,235 $3,417 $632 $3,475 $3,685 $3,625 $2,724 $5,647 $5,068
Estimated no. of 
treated patients
Treated prevalence
 

 
 0.3% $245,766 $171,678 $46,725 $115,803 $119,022 $26,532 $21,672 $174,432 $812,100 $64,920
Estimated annual 
MDD direct costs
Treated prevalence
 

 
 0.3% $1,347 $384 $160 $73 $414 $98 $79 $475 $4,586 $329
Estimated annual 
MDD direct costs
to the payor
Treated prevalence
 

 
 0.3% $1,055 $268 $123 $59 $316 $78 $57 $400 $17 $263
Cost Savings
 
†
 
Treated prevalence
 

 
 0.3% $18,285 $1,600 $12,618 ($4,427) $5,754 $7,500 $7,233 $8,268 $29,049 $12,137
 
*All costs in (US$) millions.
 
†
 
Comparison in the estimated cost savings or (loss) with a population assuming a treated population of 1 million with 100% coverage for each 1% of venlafaxine
market share. MDD, major depressive disorder.
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with a baseline daily treatment cost of $2.54 can in-
crease by almost four-fold to $9.23 and $10.52, re-
spectively, before reaching equivalency in expected
cost with the SSRIs and TCAs. Alternatively, Table 13
shows that venlafaxine’s baseline efficacy rate of
62.3% in the inpatient setting could drop as much
as 53.9% and 52.3%, respectively, to reach cost-
effectiveness profiles equivalent to those of SSRIs
and TCAs. Similar conclusions can be drawn from
results in the other countries.
Although not consistent with the results of our
pharmacoeconomic analysis, the Monte Carlo sim-
ulation revealed with levels of certainty ranging
from 82% to 99% that venlafaxine IR was a sig-
nificantly lower cost alternative in 9 out of the 10
countries vs. the SSRIs and TCAs in both the in-
patient and outpatient settings. Table 14 presents
the differences in expected costs of the Monte Carlo
simulation expressed in mean differences with upper
and lower limits and standard deviations for the dis-
tribution curve. The difference in expected cost be-
tween venlafaxine and SSRIs in the inpatient set-
ting ranged from $59.92 in Venezuela to $1404 in
the Netherlands. Within the outpatient setting, the
difference in expected costs between venlafaxine and
SSRIs ranged from $73.68 in Venezuela to $488.07 in
Germany. Poland was the only country in which the
expected costs of venlafaxine were higher than the
SSRIs and TCAs resulting in a negative mean value.
Table 15 depicts the results of the Monte Carlo
simulation expressed in terms of differences in mean
Symptom-Free Days between venlafaxine vs. the
SSRIs or TCAs. Consistent with the results of the
pharmacoeconomic analysis, venlafaxine was a more
effective treatment in terms of SFDs in comparison
with either SSRIs or TCAs in both treatment set-
tings for all 10 countries. In the inpatient setting,
the greatest mean difference in SFDs was noted in
Venezuela, where treatment with venlafaxine resulted
in 10.08 more SFDs vs. the TCAs while the lowest
difference was seen in UK, where venlafaxine resulted
in only 3.39 additional SFDs over the SSRIs.
 
Table 12
 
Break-even analysis: daily cost of drug treatment
 
Inpatient Outpatient
Break-even points Break-even points
Venlafaxine daily cost w/SSRIs w/TCAs Venlafaxine daily cost w/SSRIs w/TCAs
Germany $2.54 $9.23 $10.52 $2.54 $6.17 $6.40
Italy $1.24 $3.63 $5.26 $2.48 $2.52 $2.23
Netherlands $1.46 $11.43 $12.70 $1.46 $3.20 $3.45
Poland $1.99 $0.88 $0.82 $1.99 $0.88 $0.82
Spain $1.28 $3.01 $3.64 $2.07 $2.98 $2.90
Sweden $1.81 $3.78 $4.52 $2.23 $3.41 $3.27
Switzerland $1.95 $10.23 $14.78 $1.95 $4.01 $4.25
UK $1.70 $8.55 $6.11 $1.70 $4.76 $3.73
USA $2.46 $13.80 $15.85 $2.46 $8.50 $8.62
Venezuela $2.76 $30.00 $18.72 $2.76 $4.60 $6.11
 
SSRIs, selective serotonin reuptake inhibitors; TCAs, tricyclic antidepressants.
 
Table 13
 
Break-even analysis: efficacy rates
 
Inpatient Outpatient
Break-even points Break-even points
Venlafaxine efficacy rate w/SSRIs w/TCAs Venlafaxine efficacy rate w/SSRIs w/TCAs
Germany 62.3% 53.9% 52.3% 70.2% 57.1% 56.3%
Italy 62.3% 54.0% 50.2% 70.2% 69.5% 75.1%
Netherlands 62.3% 50.9% 52.2% 70.2% 54.8% 52.6%
Poland 62.3% 177.0% 173.0% 70.2% n/a n/a
Spain 62.3% 54.7% 51.9% 70.2% 60.9% 61.7%
Sweden 62.3% 61.1% 62.1% 70.2% 61.1% 62.1%
Switzerland 62.3% 53.1% 48.4% 70.2% 54.0% 49.6%
UK 62.3% 52.1% 51.9% 70.2% 49.4% 56.0%
USA 62.3% 52.3% 50.4% 70.2% 53.3% 53.0%
Venezuela 62.3% 53.9% 50.8% 70.2% 57.0% 51.7%
 
SSRIs, selective serotonin reuptake inhibitors; TCAs tricyclic antidepressants.
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Discussion
 
This study confirms results of previous pharmaco-
economic analyses in its conclusion that the use of
venlafaxine is a cost-effective strategy for the treat-
ment of MDD for both inpatients and outpatients
across diverse health care systems. In addition, initi-
ating treatment with venlafaxine provides the low-
est expected cost when all downstream costs are
considered in the analysis of alternative antidepres-
sant agents. The superior pharmacoeconomic pro-
file of venlafaxine is attributable to its high success
rate and low ADR dropout rate as reported in Table
1 of our analysis.
Treatment success rates and drop-out rates due
to either lack of efficacy or adverse drug reactions
were the greatest drivers of the decision analytic
model in all countries, and therefore had a signifi-
cant impact on the expected costs of treatment. This
observation explains why improvements in treatment
success with venlafaxine resulted in lower expected
costs in most countries. Since venlafaxine showed a
dominant cost-effectiveness profile in terms of ex-
pected costs per success over the SSRIs and TCAs in
most countries, an incremental cost-effectiveness anal-
ysis was not appropriate.
Significant variations were observed among coun-
tries in both the magnitude of the difference between
the comparators and the confidence of the ranking.
These differences were due partly to variations in
clinical practice patterns and partly to differences in
the cost of health care services and drug prices. For
example, in the Netherlands, due to the less restric-
tive policies regarding the length of inpatient stay
for MDD patients, the costs of the failure arms in
the model were larger compared to success arms in
most of the other countries. As a consequence ven-
lafaxine showed a greater advantage in the Nether-
lands, in terms of cost-avoidance due to its higher
expected success rate. The same effect is evident in
Venezuela where the cost of an inpatient stay is
high relative to the cost of pharmaceuticals. In Po-
land, the situation is reversed, since the cost of
health care services relative to the cost of antide-
pressants is small and therefore the avoided cost
of failure branches in the model are modest. As a
result, the savings in health care resources con-
sumed due to the higher success rate did not offset
the higher cost of venlafaxine relative to the other
comparators.
The results of this study attempt to reflect the
implications of drug selection for the typical MDD
patient in the acute phase. However, the signifi-
cant individual patient variations and differences
in practice patterns may compromise the external
validity (i.e., generalizability) of the evaluation.
Additionally, the deterministic model design and
secondary data employed in this evaluation intro-
duce potential information bias to the data analy-
 
Table 14
 
Monte Carlo analysis: differences in expected cost
 
Inpatient Outpatient
venlafaxine vs. SSRIs venlafaxine vs. TCAs venlafaxine vs. SSRIs venlafaxine vs. TCAs
Mean SD Mean SD Mean SD Mean SD
Germany $798.12 $749.49 $1,014.01 $722.79 $488.07 $203.20 $519.31 $203.86
Italy $363.91 $338.32 $530.98 $378.85 $17.24 $45.31
 

 
$3.20 $51.01
Netherlands $1,404.11 $857.03 $1,639.50 $863.46 $329.57 $90.51 $48.99 $96.27
Poland
 

 
$91.18 $90.96
 

 
$109.40 $116.12
 

 
$142.42 $7.46
 

 
$147.17 $14.05
Spain $256.09 $270.42 $402.47 $287.95 $144.37 $87.30 $131.99 $93.57
Sweden $298.93 $358.47 $569.16 $382.94 $211.84 $118.62 $187.65 $121.13
Switzerland $518.11 $429.79 $819.33 $611.37 $189.22 $61.07 $192.90 $108.80
UK $367.13 $402.02 $587.68 $452.61 $221.28 $75.87 $287.01 $112.86
USA $877.67 $245.99 $893.71 $240.86 $877.67 $245.99 $893.71 $240.86
Venezuela $59.92 $8.71 $780.31 $778.45 $73.68 $36.43 $450.16 $192.02
 
SSRIs, selective serotonin reuptake inhibitors; TCAs, tricyclic anitdepressants.
 
Table 15
 
Monte Carlo analysis: differences in symptom-
free day
 
Inpatient Outpatient
venlafaxine 
vs. SSRIs
venlafaxine 
vs. TCAs
venlafaxine 
vs. SSRIs
venlafaxine 
vs. TCAs
Mean SD Mean SD Mean SD Mean SD
Germany 6.4 5.9 8.2 5.6 10.9 4.0 12.9 3.6
Italy 7.2 6.4 9.1 6.7 12.0 4.1 17.4 4.4
Netherlands 7.6 5.4 9.6 8.2 14.1 3.8 18.2 4.6
Poland 6.2 3.7 9.5 4.2 13.9 3.6 17.0 4.3
Spain 6.7 5.9 9.4 5.8 10.8 3.9 13.4 4.0
Sweden 6.0 6.0 9.4 5.9 11.0 3.9 13.6 4.1
Switzerland 3.4 3.0 6.8 4.5 5.9 2.1 9.2 3.2
UK 2.9 7.4 8.3 8.9 4.9 2.9 12.9 3.9
USA 7.3 5.1 8.8 6.1 11.1 3.1 13.2 2.8
Venezuela 3.4 3.1 10.1 6.7 5.4 1.9 18.2 4.5
 
SSRIs, selective serotonin reuptake inhibitors; TCAs, tricyclic antidepressants.
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sis. In an effort to mitigate this bias, comprehen-
sive sensitivity analysis was conducted.
The validity of the pharmacoeconomic model
was demonstrated through rigorous sensitivity analy-
ses and expert review. Practicing clinicians and local
health economists from each country collaborated in
the analytic approach and reviewed the methodology
against local criteria for health care decision-making.
Our cost-effectiveness analysis extracted the efficacy
and dropout rates from two published meta-analy-
ses [20, 21]. A statistical analysis demonstrated
with 95% confidence that the three comparators
were statistically different. Furthermore, both meta-
analyses employed strict inclusion/exclusion criteria
for selecting MDD patient samples, types of treat-
ment comparators and the measurement of treat-
ment success. All these clinical trial variables are
critical elements in reducing the potential for bias
and promoting the homogeneity of the input data
to justify treatment success in the typical MDD
patient. Despite the implementation of rigorous
selection criteria, the authors of the meta-analyses
did concede that the potential for bias might exist
since clinical trials assessing newer agents usually
report higher rates of efficacy than the more estab-
lished treatments. Ironically, one reason may be
due to the more homogeneous patient sample se-
lection in these studies assessing newer antidepres-
sant treatments. It is apparent that our research
represents the first effort to study the economics of
antidepressants on such a large scale. We are there-
fore confident in the generalizability of the results.
It is important to note that the conclusions of
pharmacoeconomic research often encourage the
selection of drugs that provide additional benefit
in terms of improved health outcome notwithstand-
ing an incremental investment for that improve-
ment (i.e., greater expected cost). However, manag-
ing MDD patients with venlafaxine provides less
overall financial expenditure in addition to im-
proved health outcome. Viewing health care as an
investment, venlafaxine represents excellent value
for money. From a policy perspective, configuring
payers’ antidepressant portfolios to include a
greater share of venlafaxine will likely reduce total
health care expenditures, as well as improve pop-
ulation health. For each additional 1% of venla-
faxine market share, average savings for the 10
countries are estimated at $9,892, based on a pop-
ulation of 1 million, ranging from $1,600 (Italy)
to $29,049 (US). Additionally, the utilization of
venlafaxine is expected to provide each treated pa-
tient with a greater reduction in depressive symp-
toms compared to other treatments.
When considering the various cost-containment
strategies in health care systems across the world,
from fixed budgets for doctors and pharmaceuti-
cal expenditures to rationing products and ser-
vices, an optimal strategy to limit the growth of
health care costs should focus on the system-wide
costs. Optimal health economic efficiency can only
be realized when a collective, rather than segmented
(e.g., drug acquisition) budget is considered that ac-
counts for total treatment costs and how those
treatment costs change based on the uncertainty of
health care intervention. In this way, treatment con-
sequences, and not just “up-front” expenditures will
figure into the equation of health care budgeting.
The results of this international study of system-
wide health care costs suggest that increased utili-
zation of venlafaxine for patients with Major De-
pressive Disorder in most health care settings will
favorably impact payer budgets as well as improve
patient mental health outcomes.
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